Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Correction: Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency.

Dheekollu J, Malecka K, Wiedmer A, Delecluse HJ, Chiang AKS, Altieri DC, Messick TE, Lieberman PM.

Oncotarget. 2019 Jul 8;10(43):4505-4506. doi: 10.18632/oncotarget.27073. eCollection 2019 Jul 8.

2.

Structural Basis for Cooperative Binding of EBNA1 to the Epstein-Barr Virus Dyad Symmetry Minimal Origin of Replication.

Malecka KA, Dheekollu J, Deakyne JS, Wiedmer A, Ramirez UD, Lieberman PM, Messick TE.

J Virol. 2019 Sep 30;93(20). pii: e00487-19. doi: 10.1128/JVI.00487-19. Print 2019 Oct 15.

PMID:
31142669
3.

Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth.

Messick TE, Smith GR, Soldan SS, McDonnell ME, Deakyne JS, Malecka KA, Tolvinski L, van den Heuvel APJ, Gu BW, Cassel JA, Tran DH, Wassermann BR, Zhang Y, Velvadapu V, Zartler ER, Busson P, Reitz AB, Lieberman PM.

Sci Transl Med. 2019 Mar 6;11(482). pii: eaau5612. doi: 10.1126/scitranslmed.aau5612.

PMID:
30842315
4.

Structural and Functional Basis for an EBNA1 Hexameric Ring in Epstein-Barr Virus Episome Maintenance.

Deakyne JS, Malecka KA, Messick TE, Lieberman PM.

J Virol. 2017 Sep 12;91(19). pii: e01046-17. doi: 10.1128/JVI.01046-17. Print 2017 Oct 1.

5.

Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency.

Dheekollu J, Malecka K, Wiedmer A, Delecluse HJ, Chiang AK, Altieri DC, Messick TE, Lieberman PM.

Oncotarget. 2017 Jan 31;8(5):7248-7264. doi: 10.18632/oncotarget.14540. Erratum in: Oncotarget. 2019 Jul 08;10(43):4505-4506.

6.

Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.

Owusu BY, Bansal N, Venukadasula PK, Ross LJ, Messick TE, Goel S, Galemmo RA, Klampfer L.

Oncotarget. 2016 May 17;7(20):29492-506. doi: 10.18632/oncotarget.8785.

7.

Computational analysis of EBNA1 "druggability" suggests novel insights for Epstein-Barr virus inhibitor design.

Gianti E, Messick TE, Lieberman PM, Zauhar RJ.

J Comput Aided Mol Des. 2016 Apr;30(4):285-303. doi: 10.1007/s10822-016-9899-y. Epub 2016 Apr 5.

8.

Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor Activation.

Venukadasula PK, Owusu BY, Bansal N, Ross LJ, Hobrath JV, Bao D, Truss JW, Stackhouse M, Messick TE, Klampfer L, Galemmo RA Jr.

ACS Med Chem Lett. 2015 Dec 22;7(2):177-81. doi: 10.1021/acsmedchemlett.5b00357. eCollection 2016 Feb 11.

9.

Disruption of host antiviral resistances by gammaherpesvirus tegument proteins with homology to the FGARAT purine biosynthesis enzyme.

Tsai K, Messick TE, Lieberman PM.

Curr Opin Virol. 2015 Oct;14:30-40. doi: 10.1016/j.coviro.2015.07.008. Epub 2015 Aug 7. Review.

10.

Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer.

Domchek SM, Tang J, Stopfer J, Lilli DR, Hamel N, Tischkowitz M, Monteiro AN, Messick TE, Powers J, Yonker A, Couch FJ, Goldgar DE, Davidson HR, Nathanson KL, Foulkes WD, Greenberg RA.

Cancer Discov. 2013 Apr;3(4):399-405. doi: 10.1158/2159-8290.CD-12-0421. Epub 2012 Dec 26.

11.

Differential regulation of JAMM domain deubiquitinating enzyme activity within the RAP80 complex.

Patterson-Fortin J, Shao G, Bretscher H, Messick TE, Greenberg RA.

J Biol Chem. 2010 Oct 1;285(40):30971-81. doi: 10.1074/jbc.M110.135319. Epub 2010 Jul 22.

12.

Crystal structure and functional interpretation of the erythrocyte spectrin tetramerization domain complex.

Ipsaro JJ, Harper SL, Messick TE, Marmorstein R, Mondragón A, Speicher DW.

Blood. 2010 Jun 10;115(23):4843-52. doi: 10.1182/blood-2010-01-261396. Epub 2010 Mar 2.

13.

The ubiquitin landscape at DNA double-strand breaks.

Messick TE, Greenberg RA.

J Cell Biol. 2009 Nov 2;187(3):319-26. doi: 10.1083/jcb.200908074. Review.

14.

Familial breast cancer screening reveals an alteration in the RAP80 UIM domain that impairs DNA damage response function.

Nikkilä J, Coleman KA, Morrissey D, Pylkäs K, Erkko H, Messick TE, Karppinen SM, Amelina A, Winqvist R, Greenberg RA.

Oncogene. 2009 Apr 23;28(16):1843-52. doi: 10.1038/onc.2009.33. Epub 2009 Mar 23.

15.

MERIT40 controls BRCA1-Rap80 complex integrity and recruitment to DNA double-strand breaks.

Shao G, Patterson-Fortin J, Messick TE, Feng D, Shanbhag N, Wang Y, Greenberg RA.

Genes Dev. 2009 Mar 15;23(6):740-54. doi: 10.1101/gad.1739609. Epub 2009 Mar 4.

16.

Structural basis for ubiquitin recognition by the Otu1 ovarian tumor domain protein.

Messick TE, Russell NS, Iwata AJ, Sarachan KL, Shiekhattar R, Shanks JR, Reyes-Turcu FE, Wilkinson KD, Marmorstein R.

J Biol Chem. 2008 Apr 18;283(16):11038-49. doi: 10.1074/jbc.M704398200. Epub 2008 Feb 12.

17.

Supplemental Content

Loading ...
Support Center